We could all use a little IT help right now. Photo by Maskot/Getty

Though it's been around since 2012, JPMorgan Chase's Force for Good program feels especially vital right now. The project connects Chase employee volunteers with hundreds of nonprofits around the world to build sustainable tech solutions that help advance their missions.

Even better, Houston and Dallas nonprofits have a leg up in the selection process. Organizations located in or near one of Chase's tech centers get priority, and that includes H-Town and Big D.

The government-registered nonprofits, foundations, and social enterprises (we're talking everything from food banks to theater companies) selected to participate will have access to a team of up to 10 highly skilled technologists, who will spend approximately four hours per week advising over an eight month period.

Each nonprofit is asked to propose the specific project that would benefit from technology guidance, and it needs to be something the organization can maintain when the project period is over.

"We have more than 50,000 technologists at JPMorgan Chase around the world and they're passionate about giving back," says Ed Boden, global lead of Technology for Social Good programs. "Force for Good gives our employees the opportunity to utilize their unique skills while also learning new ones, to build technology solutions for the organizations that need it most."

If you're the director, CEO, or other person in charge at a nonprofit and you still have questions about Force for Good, Chase has put together a free webinar to help explain further.

These webinars cover the overall program experience and application process, and it's highly recommended that nonprofits watch before applying. The live webinar dates (with Texas times) are June 2 from 1:30-2:30 pm and June 8 from 10:30-11:30 am.

A pre-recorded webinar will also be available for nonprofits to review after the live webinar dates.

Since 2012, Force for Good has worked with over 320 organizations in 22 cities, contributing over 190,500 hours of knowledge and skills.

"It is a great program that can provide strong impact for nonprofit organizations that need technology help," says Chris Rapp, a Dallas-based Chase executive. "As a father and husband of two Dallas artists, I am a huge believer in helping the arts grow and hopefully we can help do this through Force For Good."

The application process opened on May 28, with a deadline to submit by July 10.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.